vs
Side-by-side financial comparison of Atara Biotherapeutics, Inc. (ATRA) and T Stamp Inc (IDAI). Click either name above to swap in a different company.
Atara Biotherapeutics, Inc. is the larger business by last-quarter revenue ($1.6M vs $908.9K, roughly 1.8× T Stamp Inc). On growth, T Stamp Inc posted the faster year-over-year revenue change (-39.3% vs -95.1%). Over the past eight quarters, T Stamp Inc's revenue compounded faster (25.9% CAGR vs -75.9%).
Atara Biotherapeutics, Inc. is a clinical-stage biotechnology company focused on developing allogeneic T-cell immunotherapies for patients with unmet medical needs across oncology, autoimmune disease, and infectious disease indications. It operates primarily in North America, Europe, and Asia-Pacific, partnering with research institutions to advance its novel treatment pipeline.
T Stamp Inc, trading under ticker IDAI, develops AI-powered identity verification, trust scoring, and fraud prevention solutions. It serves clients across fintech, healthcare, and e-commerce segments, primarily operating in North America to help organizations securely authenticate user identities and mitigate fraud risks.
ATRA vs IDAI — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $1.6M | $908.9K |
| Net Profit | — | $-2.5M |
| Gross Margin | — | — |
| Operating Margin | — | -224.9% |
| Net Margin | — | -279.9% |
| Revenue YoY | -95.1% | -39.3% |
| Net Profit YoY | 73.2% | 57.7% |
| EPS (diluted) | — | $-0.37 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $1.6M | $908.9K | ||
| Q3 25 | $3.5M | $872.5K | ||
| Q2 25 | $17.6M | $812.7K | ||
| Q1 25 | $98.1M | $545.5K | ||
| Q4 24 | $32.8M | $1.5M | ||
| Q3 24 | $40.2M | $511.1K | ||
| Q2 24 | $28.6M | $500.4K | ||
| Q1 24 | $27.4M | $573.7K |
| Q4 25 | — | $-2.5M | ||
| Q3 25 | $-4.3M | $-1.9M | ||
| Q2 25 | $2.4M | $-1.7M | ||
| Q1 25 | $38.0M | $-2.2M | ||
| Q4 24 | $-12.7M | $-6.0M | ||
| Q3 24 | $-21.9M | $-1.3M | ||
| Q2 24 | $-19.0M | $-2.6M | ||
| Q1 24 | $-31.8M | $-2.7M |
| Q4 25 | — | -224.9% | ||
| Q3 25 | -103.5% | -203.0% | ||
| Q2 25 | 18.2% | -207.0% | ||
| Q1 25 | 39.5% | -396.5% | ||
| Q4 24 | -37.3% | -81.2% | ||
| Q3 24 | -54.1% | -523.7% | ||
| Q2 24 | -63.7% | -524.7% | ||
| Q1 24 | -114.2% | -496.7% |
| Q4 25 | — | -279.9% | ||
| Q3 25 | -124.6% | -219.1% | ||
| Q2 25 | 13.6% | -210.7% | ||
| Q1 25 | 38.7% | -395.5% | ||
| Q4 24 | -38.8% | -401.5% | ||
| Q3 24 | -54.5% | -245.7% | ||
| Q2 24 | -66.5% | -519.3% | ||
| Q1 24 | -116.1% | -466.9% |
| Q4 25 | — | $-0.37 | ||
| Q3 25 | $-0.32 | $-0.72 | ||
| Q2 25 | $0.19 | $-0.69 | ||
| Q1 25 | $3.50 | $-0.89 | ||
| Q4 24 | $0.27 | $-3.14 | ||
| Q3 24 | $-2.93 | $-1.06 | ||
| Q2 24 | $-3.10 | $-3.19 | ||
| Q1 24 | $-5.65 | $-3.97 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $8.5M | $6.0M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $-38.5M | $8.7M |
| Total Assets | $20.2M | $11.2M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $8.5M | $6.0M | ||
| Q3 25 | $13.7M | $5.4M | ||
| Q2 25 | $22.3M | $292.1K | ||
| Q1 25 | $13.8M | $1.1M | ||
| Q4 24 | $42.5M | $2.8M | ||
| Q3 24 | $67.2M | $598.0K | ||
| Q2 24 | $35.3M | $659.5K | ||
| Q1 24 | $46.2M | $816.7K |
| Q4 25 | $-38.5M | $8.7M | ||
| Q3 25 | $-36.6M | $6.1M | ||
| Q2 25 | $-35.0M | $2.4M | ||
| Q1 25 | $-55.1M | $4.1M | ||
| Q4 24 | $-97.3M | $3.0M | ||
| Q3 24 | $-90.5M | $5.4M | ||
| Q2 24 | $-110.9M | $750.4K | ||
| Q1 24 | $-98.3M | $1.4M |
| Q4 25 | $20.2M | $11.2M | ||
| Q3 25 | $30.2M | $11.2M | ||
| Q2 25 | $36.9M | $5.7M | ||
| Q1 25 | $62.0M | $6.6M | ||
| Q4 24 | $109.1M | $8.6M | ||
| Q3 24 | $142.7M | $10.6M | ||
| Q2 24 | $117.3M | $5.2M | ||
| Q1 24 | $165.3M | $5.6M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-50.9M | $2.0M |
| Free Cash FlowOCF − Capex | — | $2.0M |
| FCF MarginFCF / Revenue | — | 215.4% |
| Capex IntensityCapex / Revenue | 0.0% | 0.8% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $-5.7M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-50.9M | $2.0M | ||
| Q3 25 | $-9.8M | $-4.0M | ||
| Q2 25 | $-7.3M | $-2.1M | ||
| Q1 25 | $-28.1M | $-1.5M | ||
| Q4 24 | $-24.5M | $-2.7M | ||
| Q3 24 | $-4.0M | $-2.4M | ||
| Q2 24 | $-10.6M | $-1.6M | ||
| Q1 24 | $-29.6M | $-2.2M |
| Q4 25 | — | $2.0M | ||
| Q3 25 | — | $-4.0M | ||
| Q2 25 | — | $-2.1M | ||
| Q1 25 | — | $-1.6M | ||
| Q4 24 | $-24.6M | $-2.7M | ||
| Q3 24 | — | $-2.4M | ||
| Q2 24 | $-10.7M | $-1.6M | ||
| Q1 24 | $-29.7M | $-2.2M |
| Q4 25 | — | 215.4% | ||
| Q3 25 | — | -459.6% | ||
| Q2 25 | — | -258.6% | ||
| Q1 25 | — | -289.2% | ||
| Q4 24 | -75.0% | -182.9% | ||
| Q3 24 | — | -475.4% | ||
| Q2 24 | -37.3% | -320.9% | ||
| Q1 24 | -108.7% | -376.6% |
| Q4 25 | 0.0% | 0.8% | ||
| Q3 25 | 0.0% | 0.0% | ||
| Q2 25 | 0.0% | 0.2% | ||
| Q1 25 | 0.0% | 6.8% | ||
| Q4 24 | 0.3% | 0.1% | ||
| Q3 24 | 0.0% | 0.7% | ||
| Q2 24 | 0.1% | 1.3% | ||
| Q1 24 | 0.5% | 0.5% |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | -3.07× | — | ||
| Q1 25 | -0.74× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
